GILEAD SCIENCES INC

Gilead CFO Andrew Dickinson’s routine 3,000‑share sale shows disciplined insider liquidity amid a 26.9% YTD gain, supporting a steady, positive outlook.

Inside Gilead: Erin Burkhart’s 2026 trades reveal a strategic mix of buying RSUs, selling shares, and hedging with derivatives—showing long‑term confidence amid short‑term volatility.

Insights on Gilead Sciences insider selling: CFO Andrew Dickinson’s 3,000‑share rule‑plan trades signal disciplined liquidity management, not distress, amid strong biotech growth.